首页> 美国卫生研究院文献>Scientific Reports >Potent Paracrine Effects of human induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells Attenuate Doxorubicin-induced Cardiomyopathy
【2h】

Potent Paracrine Effects of human induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells Attenuate Doxorubicin-induced Cardiomyopathy

机译:人类诱导的多能干细胞来源的间充质干细胞的强旁分泌作用减弱阿霉素诱导的心肌病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Transplantation of bone marrow mesenchymal stem cells (BM-MSCs) can protect cardiomyocytes against anthracycline-induced cardiomyopathy (AIC) through paracrine effects. Nonetheless the paracrine effects of human induced pluripotent stem cell-derived MSCs (iPSC-MSCs) on AIC are poorly understood. In vitro studies reveal that doxorubicin (Dox)-induced reactive oxidative stress (ROS) generation and cell apoptosis in neonatal rat cardiomyocytes (NRCMs) are significantly reduced when treated with conditioned medium harvested from BM-MSCs (BM-MSCs-CdM) or iPSC-MSCs (iPSC-MSCs-CdM). Compared with BM-MSCs-CdM, NRCMs treated with iPSC-MSCs-CdM exhibit significantly less ROS and cell apoptosis in a dose-dependent manner. Transplantation of BM-MSCs-CdM or iPSC-MSCs-CdM into mice with AIC remarkably attenuated left ventricular (LV) dysfunction and dilatation. Compared with BM-MSCs-CdM, iPSC-MSCs-CdM treatment showed better alleviation of heart failure, less cardiomyocyte apoptosis and fibrosis. Analysis of common and distinct cytokines revealed that macrophage migration inhibitory factor (MIF) and growth differentiation factor-15 (GDF-15) were uniquely overpresented in iPSC-MSC-CdM. Immunodepletion of MIF and GDF-15 in iPSC-MSCs-CdM dramatically decreased cardioprotection. Injection of GDF-15/MIF cytokines could partially reverse Dox-induced heart dysfunction. We suggest that the potent paracrine effects of iPSC-MSCs provide novel “cell-free” therapeutic cardioprotection against AIC, and that MIF and GDF-15 in iPSC-MSCs-CdM are critical for these enhanced cardioprotective effects.
机译:骨髓间充质干细胞(BM-MSC)的移植可以通过旁分泌作用保护心肌细胞免受蒽环类药物引起的心肌病(AIC)的侵害。然而,人们对人诱导的多能干细胞来源的MSC(iPSC-MSC)对AIC的旁分泌作用了解甚少。体外研究表明,用从BM-MSC(BM-MSCs-CdM)或iPSC收集的条件培养基处理后,新生大鼠心肌细胞(NRCM)中阿霉素(Dox)诱导的反应性氧化应激(ROS)生成和细胞凋亡显着减少-MSC(iPSC-MSCs-CdM)。与BM-MSCs-CdM相比,用iPSC-MSCs-CdM处理的NRCM以剂量依赖性方式表现出明显更少的ROS和细胞凋亡。将BM-MSCs-CdM或iPSC-MSCs-CdM移植到患有AIC的小鼠中可显着减轻左心室(LV)功能障碍和扩张。与BM-MSCs-CdM相比,iPSC-MSCs-CdM治疗可更好地缓解心力衰竭,减少心肌细胞凋亡和纤维化。常见和独特细胞因子的分析表明,巨噬细胞迁移抑制因子(MIF)和生长分化因子15(GDF-15)在iPSC-MSC-CdM中是唯一被过度表达的。 iPSC-MSCs-CdM中MIF和GDF-15的免疫耗竭显着降低了心脏保护作用。注射GDF-15 / MIF细胞因子可以部分逆转Dox引起的心脏功能障碍。我们建议,iPSC-MSC的强旁分泌作用提供了针对AIC的新型“无细胞”治疗性心脏保护,而iPSC-MSCs-CdM中的MIF和GDF-15对于这些增强的心脏保护作用至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号